Research programme: inflammation therapy - Amgen/Schering-Plough
Latest Information Update: 08 Sep 2008
At a glance
- Originator Amgen; Schering-Plough
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 08 Sep 2008 Discontinued - Preclinical for Inflammation in USA (unspecified route)
- 22 Feb 2005 NeoGenesis has been acquired and merged into Schering-Plough
- 06 Aug 2003 Preclinical trials in Inflammation in USA (unspecified route)